“…Although 99mTc-sestamibi was developed initially as an agent for MPI, several studies have shown that it accumulates in cardiac and extracardiac tissues, depending on the etiologic processes involved. An intense and discrete uptake of the radiotracer is commonly seen with viable tumors including thyroid ( 1 ), breast ( 2 , 3 ), lung cancers, lymphomas ( 4 , 5 , 6 ), musculoskeletal sarcomas ( 7 ), and carcinoid tumors ( 8 ); focal inflammatory processes and pulmonary thromboembolism (PE) ( 9 ) also demonstrate a similar uptake. On the other hand, a diffuse increase in the pulmonary uptake of 99m Tc sestamibi occurs in a variety of inflammatory and hypermetabolic processes affecting the myocardial and pulmonary tissues.…”